- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Diseases
FDA wants further testing of Lilly pancreas drug
April 16, 2011
Associated PressEli Lilly and Co. Inc. said Friday that the FDA has asked the drugmaker to conduct another clinical trial of its proposed
pancreas drug before it resubmits an application to have the drug approved for sale.
MoreFirm joins race with IU autism drug
April 9, 2011
J.K. WallThe Indiana University School of Medicine has licensed a pediatric psychiatrist's patent on
an alcohol-dependency drug that the doctor discovered improves the language and social skills of autism patients. IU has licensed
the patent to Indianapolis-based Confluence Pharmaceuticals Inc.
MoreRegulators delay approval of Lilly's Alzheimer’s screen
March 18, 2011
Bloomberg NewsThe Food and Drug Administration said Lilly needs to create a training program to ensure brain scans are interpreted properly.
MoreTrade agency to probe Lilly's infringement claim
March 17, 2011
Bloomberg NewsEli Lilly and Co.’s patent-infringement claim over Hospira Inc.’s generic version of the cancer treatment Gemzar will be investigated
by a U.S. trade agency with the power to block imports of the copycat drug.
MoreLilly's Bydureon falls short of competitor in study
March 3, 2011
Bloomberg NewsBydureon, the diabetes drug being developed by Amylin Pharmaceuticals Inc., Eli Lilly and Co. and Alkermes Inc., didn’t
control the disease better than Novo Nordisk A/S’s Victoza in a study.
MoreRepeated price cuts take glow off Endocyte IPO
February 12, 2011
Greg AndrewsNew investors got in for $6 a share—which is less than the average price paid by prior investors, a regulatory filing
reveals.
MoreDiabetes boom sparks Roche expansion
February 12, 2011
J.K. WallRoche Diagnostics Corp. is expanding one of its Indianapolis manufacturing plants to keep up with growing sales of its leading
brand of blood glucose monitors.
MoreHead of Lilly's oncology unit resigning
January 25, 2011
John H. Johnson has been hired as CEO by East Brunswick, N.J.-based biotechnology company Savient Pharmaceuticals Inc.
MoreLilly imaging drug isn't ready for approval, FDA says
January 18, 2011
Eli Lilly and Co.’s experimental drug to help identify plaque in the brain tied to Alzheimer's disease isn't ready for approval,
according to U.S. regulators.
MoreLilly's Solpura may lack data to prove effectiveness
January 10, 2011
Bloomberg NewsOutside advisers to the FDA will meet Jan. 12 to review whether the drug should be approved for people with pancreas insufficiency
caused by cystic fibrosis, chronic pancreatitis or other conditions.
MoreRoche acquires Marcadia Biotech
December 30, 2010
Chris O'MalleyMarcadia Biotech Inc., a Carmel-based biopharmaceutical company founded by prominent scientists from Eli Lilly and Co. in
2006, has been acquired by Swiss life sciences giant Roche.
MoreLilly suspends late-stage trial for melanoma drug
December 13, 2010
Bloomberg NewsEli Lilly and Co. suspended a late-stage clinical trial of a medicine for skin-cancer patients after 12 patients in the study
died.
MoreQ&A
December 8, 2010
J.K. WallMolecular biologist,David G. Skalnik will become associate dean for research and graduate education at the
IUPUI School of Science in January. Since 1991, Skalnick has been a researcher at the Indiana University School of Medicine,
leading a team of three in the study of epigenetics—factors that influence whether certain genes are turned on or turned
off.
MoreStudy: Arthritis drug co-developed by Lilly shows promise
November 12, 2010
IBJ Staff and Bloomberg NewsLilly paid $90 million in 2009 to acquire the global rights to the treatment in a bid to beef up its pipeline of medications
for autoimmune diseases.
MoreLilly makes $300M deal for Philadelphia drug company
November 8, 2010
J.K. WallEli Lilly said it will acquire Avid Radiopharmaceuticals, maker of an experimental agent that could help identify patients
with Alzheimer's disease. The price could climb to $800 million if the agent is commercially successful.
MoreUPDATE: Lilly, others see stock slide after drug rejection
October 20, 2010
Bloomberg NewsStock in Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. dropped after they were rebuffed a second time in
a bid to gain U.S. approval of a once-weekly version of the diabetes drug Byetta.
MoreLilly's Erbitux shows mixed results in cancer studies
October 11, 2010
Bloomberg NewsIn combination with chemotherapy, the drug failed to help colon-cancer patients in a European trial but did delay the spread
of breast cancer in some patients with a certain type of aggressive tumor.
MoreDiabetes research pioneer Kirtley dies at 96
August 25, 2010
Associated PressDiabetics who control their disease with pills instead of frequent insulin injections can thank Dr. William R. Kirtley, a
groundbreaking Eli Lilly researcher.
MoreLilly halts development of Alzheimer's drug
August 17, 2010
IBJ Staff and Associated PressStudies showed that the treatment did not slow the disease's progression. It's just the latest setback for the pharmaceutical
giant, which lost a patent lawsuit over a major drug last week and faces an unprecedented number of patent expirations through
2014.
MorePositron has billion-dollar hopes for medical-imaging scanner
May 29, 2010
J.K. WallA maker of medical imaging equipment that recently moved its headquarters to Fishers has grand plans to reach $1 billion in
sales and build a multimillion-dollar cyclotron facility in five years. But history shows Positron Corp. has been far better
at losing money than making it.
MoreIndianapolis startup attacks Alzheimer's disease
May 29, 2010
Norm HeikensAgeneBio Inc. this month landed a $300,000 investment from the Indiana Seed Fund to fund operations, bolster its intellectual
property, and begin learning how to make a drug into a once-a-day pill.
MoreLilly still waiting on once-weekly Byetta
May 12, 2010
J.K. WallThe U.S. Food and Drug Administration last week pushed its self-declared deadline for rendering an approval decision on the
drug Bydureon to Oct. 22. The previous deadline was in March.
MoreNew federal funds come with big goals
May 5, 2010
J.K. WallIndiana has now received nearly $50 million in federal bucks to digitize health care around the state. But the latest grant—$16
million to the Indiana Health Information Exchange—comes with specific, ambitious goals for health care providers.
MoreHealth care bill burns local tanning industry
March 26, 2010
Anthony SchoettleWith one of the nation's largest tanning-bed manufacturers and dozens of salons in central Indiana, a 10-percent tax on tanning
could cost the region jobs.
MoreIU incubator attracts East Coast biotech startup
March 17, 2010
IBJ StaffCompanion Diagnostics Inc. moves from Connecticut to the IU Emerging Technologies Center, hopes to create 30 high-paying jobs
by 2014.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
First, the Athenaeum is going to have to get past the hurdle with the Lockerbie residents and the agreement that the parcel would be residential. Second, and in my opinion, this prime piece of property should include parking, PLUS, a black box theater(s), some market rate and affordable artist housing and a plan to renovate and reconfigure the second story theater. I would negotiate to add the DeHaan property surface parking lot into the development mix, place a one story surface parking garage on the DeHaan lot on the street level (for the Dehaan tenants use during the daytime) and add a second story to the garage that would become an addition to the current second story theater and then change the direction of the theater by moving the stage across the alley and on top of the DeHaan lot parking. You can add all the stage elements that are currently missing from the Athenaeum stage to make it more attractive for use by Ballet, Opera and traveling productions. Plus, the theater changes would probably help solve some of the soundproofing issues. Alas,it does not seem to be a part of the strategic plan to conduct a study to determine best use of the property. Seems like the current plan is a quick and easy move that ignores the property best use/potential and any strategic property planning for the effect on future generations.
I recall that MSA's pilings are still in the ground and hard to remove. It’s not likely any proposal will include significant underground construction/parking because of this. Start adding 2 floors of retail, 8 floors of parking and 5-10 floors of possible hotel, and/or 10-20 floors of residential, and you are at 30 floors already with possible expansion of all the uses. But then again I could be wrong.
Accoriding to their website there is no deadline to the Do Not Call list. What is this article referring to??
On what planet are they entitled to this largesse from the stockholders? These people make multi-million dollar salaries: Pay for your own personal travel.
It matters because they're already paid enormously fat salaries: Pay for your own personal travel. Being "taxed on it" isn't a valid excuse--so what? They're still being gifted a raft of luxury perks from somebody else's money on top of an enormous, lavish salary.